EDIT Editas Medicine, Inc.
$2.60▲ +8.33%
Healthcare
Other
After hours
$2.60▲ +0.00%
Oct 27, 4:01 PM ET
Volume 3.08M
Avg Volume (10D) 1.78M
Key Metrics & Fundamentals
Market Cap
$399.31M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.66 - 3.94
% vs 50 MA
-6.15%
% vs 200 MA
-2.64%
RSI-14
50.2
MACD Histogram
+0.0100
Beta (1Y vs SPY)
2.30
Free Cash Flow
-$29.67M
Gross Rev
$11.89M
Gross Profit
$11.89M
EBITDA
-$18.09M
COGS
–
Operating Exp
$31.78M
Operating Income
-$19.89M
EBIT
-$19.89M
Pretax Income
-$18.23M
Net Income
-$18.23M
EPS (Diluted)
-0.15
Price & Volume History
Loading chart…
Recent News
Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?
Trefis · Oct 23, 2026 1:29 PM ET
Why Should You Think About Vertex Differently Now?
Trefis · Oct 20, 2026 8:56 PM ET
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
GlobeNewswire · Oct 14, 2026 9:00 AM ET
Is Vertex Stock Worth More Than Its Competitors?
Trefis · Oct 9, 2026 11:36 AM ET
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
Zacks · Oct 9, 2026 10:53 AM ET
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires · Oct 8, 2026 3:53 PM ET
Sector Update: Healthcare
MT Newswires · Oct 8, 2026 3:27 PM ET
Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401
MT Newswires · Oct 8, 2026 2:25 PM ET
Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
Stocktwits · Oct 8, 2026 1:25 PM ET
Wells Fargo Upgrades Editas Medicine to Overweight From Equal Weight, $6 Price Target
MT Newswires · Oct 8, 2026 11:14 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See EDIT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.